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Corticotropin releasing factor-binding 
protein (CRF-BP) binds CRF and urocortin 1 
(Ucn 1) with high affinity, thus preventing CRF 
receptor (CRFR) activation. Despite recent 
progress on the molecular details that govern 
interactions between CRF family neuropeptides 
and their cognate receptors, little is known 
concerning the mechanisms that allow CRF-BP 
to bind CRF and Ucn 1 with picomolar affinity. 
We conducted a comprehensive alanine scan of 
76 evolutionarily conserved residues of CRF- 
BP and identified several residues that 
differentially affected the affinity for CRF over 
Ucn 1. We determined that both neuropeptides 
derive their similarly high affinity from distinct 
binding surfaces on CRF-BP. Alanine 
substitutions of arginine 56 (R56A) and 
aspartic acid 62 (D62A) reduce the affinity for 
CRF by approximately 100-fold, while only 
marginally affecting the affinity for Ucn 1. The 
selective reduction in affinity for CRF depends 
on glutamic acid 25 (E25) in the CRF peptide, 
as substitution of E25 reduces the affinity for 
CRF-BP by approximately two orders of 
magnitude, but only in the presence of both 
R56 and D62 in human CRF-BP. We show that 
CRF-BPR56A and CRF-BPD62A have lost the 
ability to inhibit CRFR1-mediated responses to 
CRF that activate luciferase induction in 
HEK293T cells and ACTH release from 
cultured rat anterior pituitary cells. In contrast, 
both CRF-BP mutants retain the ability to 
inhibit Ucn 1-induced CRFR1 activation. 
Collectively our findings demonstrate that 
CRF-BP has distinct and separable binding 
surfaces for CRF and Ucn 1, opening new
avenues for the design of ligand-specific 
antagonists based on CRF-BP.
Corticotropin releasing factor (CRF) is a 
41 amino acid neuropeptide characterized in 1981 
as the principal hypothalamic factor to induce the 
release of adrenocorticotropic hormone (ACTH) 
from the pituitary gland (1). Three CRF-related 
peptides, urocortin (Ucn) 1, 2 and 3, have since 
been discovered (2-5). CRF and urocortins are 
pleiotropic neuropeptides that govern functions in 
the central nervous system as well as at peripheral 
sites (6-8). CRF family peptides signal via two G- 
protein coupled receptors, CRFR1 and CRFR2. 
CRF and Ucn 1 activate both receptors, whereas 
Ucn 2 and Ucn 3 are selective agonists for 
CRFR2. Considerable progress has been made in 
recent years to unravel the molecular interactions 
that dictate the binding of CRF family peptides to 
their cognate receptors. The extracellular domain 
of CRFRs primarily interacts with the C-terminal 
residues of CRF (9-11). The N-terminal residues 
of CRF are required for receptor activation and are 
proposed to interact with the transmembrane 
region of the receptor to induce conformational 
changes that enable G-protein activation (12).
Corticotropin releasing factor-binding 
protein (CRF-BP) is a 37 kDa glycoprotein that 
was originally found to circulate in high 
concentrations in late gestational maternal plasma 
where it likely prevents inappropriate release of 
ACTH from the pituitary gland by placental- 
derived CRF (13-15). CRF-BP was named for its 
ability to bind to CRF with high affinity (16), but 
it also binds to other members of the CRF family 
of neuropeptides. Human CRF-BP has high (pM) 
affinity for rat Ucn 1 (rUcn 1) and rat/human CRF
1
(r/hCRF) and intermediate (nM) affinity for mouse 
Ucn 2. CRF-BP does not appreciably bind Ucn 3. 
The fact that CRF-BP displays no significant 
sequence similarity to any other known protein 
facilitated its characterization in early vertebrates 
and insects (17-21). Among the conserved 
structural features of CRF-BP are ten cysteine 
residues that form five consecutive disulfide 
bridges (22) as well as a single asparagine (N)- 
linked glycosylation site at position 204 reported 
to be required for CRF binding (23). As the 
affinity of CRF and Ucn 1 for CRF-BP is several­
fold higher than that for either CRFR, CRF-BP is 
generally considered an antagonist of CRFRs by 
virtue of its potential to sequester ligands. Despite 
our increasing understanding of the molecular 
interactions that underlie high potency activation 
of CRFRs, we know little about the interactions 
that facilitate binding between CRF-BP and its 
high affinity endogenous peptide ligands CRF and 
Ucn 1. Early work on a panel of truncated CRF- 
derived compounds revealed that CRF(6-33) retained 
most of the binding affinity for CRF-BP and 
therefore contained the key residues for interaction 
with CRF-BP (13,24). Scrutiny of the large 
difference in affinity between ovine CRF (oCRF) 
and r/hCRF for human CRF-BP subsequently 
pinpointed the four amino acid ARAE (alanine- 
arginine-alanine-glutamic acid) motif at positions 
22-25 of r/hCRF as crucial for the high affinity 
interaction with CRF-BP (24,25).
By contrast, insight into the regions and 
residues of CRF-BP that are responsible for ligand 
binding is scant and the CRF-BP structure is not 
known. Since CRF-BP has no known paralogous 
genes, we cannot derive structural information 
from similar folds in related proteins. On the basis 
of photoaffinity labeling experiments with 
r/hCRF(6-33), a pair of arginines in CRF-BP, R46 
and R59, was identified as part of the ligand 
binding site of rat CRF-BP for CRF (26). The 
binding interface of CRF-BP was proposed to 
consist of a linear conformation of a stretch of N- 
terminal amino acids in CRF-BP that interacts 
with the a-helical CRF peptide in antiparallel 
fashion; R46 interacting with the C-terminus and 
R59 with the N-terminus of the peptide (26). 
However, this model awaits experimental
verification. In addition to our fragmented 
understanding of the mode of interaction between 
CRF-BP and CRF, little is known about the 
mechanism that allows Ucn 1 to bind CRF-BP 
with high affinity.
In the present study we have adopted an 
alanine scanning mutagenesis approach to identify 
key residues on CRF-BP that mediate binding to 
r/hCRF and rUcn 1. Interestingly, this approach 
allowed us to identify several amino acid residues 
on CRF-BP that selectively mediate binding of 
CRF but not Ucn 1. The selectively disrupted 
affinity for r/hCRF of these CRF-BP mutants 
abrogates the ability to block CRF-induced 
activation of CRFR1, while the inhibition of rUcn 
1 is unaffected.
EXPERIMENTAL PROCEDURES
Mutagenesis approach- Human CRF-BP was 
cloned into the EcoRV and Notl sites of the 
pcDNA3.1 expression vector (Invitrogen, 
Carlsbad, CA) with a FLAG-tag (DYKDDDK) at 
the N-terminus. Single amino acid mutations were 
introduced by site-specific primers in a PCR-based 
mutagenesis strategy using high fidelity Taq DNA 
polymerase (Bio-X-act, Bioline USA Inc., 
Randolph, MA). Vector from individual clones 
was purified (miniprep, Qiagen, Valencia, CA) 
and verified by automated sequencing of both 
strands. Clones that carried the desired mutation 
only were grown up in a larger volume. Vector 
DNA was isolated using a maxiprep kit (Qiagen, 
Valencia, CA) according to the manufacturer’s 
protocol and verified once more by automated 
sequencing.
Protein expression and purification- The 
pcDNA3.1 expression vector containing CRF-BP 
was introduced into human embryonic kidney 
293 T (HEK293T) cells by transient transfection 
with polyethylenimine (PEI; Sigma, St. Louis, 
MO) as the precipitating agent. Briefly, 14.4 ^g 
DNA was premixed with 36 ^g PEI in 1 ml of 
serum free media (DME) containing 
penicillin/streptomycin and glutamine (Invitrogen, 
Carlsbad, CA). DNA was allowed to precipitate 
for 10 min before dispersal over the surface of a 
40-60% confluent 15 cm petri dish containing
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serum free media. The following morning media 
was replaced by serum-free expression media 
without phenol red (Freestyle 293 expression 
media; Invitrogen, Carslbad, CA). Expression 
media was harvested after 48 h and cells and cell 
debris were removed by centrifugation. CRF-BP 
was purified by overnight incubation with 50 ^l of 
a 50% slurry of anti-FLAG agarose beads (Sigma, 
St. Louis, MO) and eluted from the resin using 
100 mM glycine pH 3.0. The pH was neutralized 
by the addition of 20% (v/v) 0.5 M Tris-HCl/1.5 
M NaCl pH 7.4. Protein expression was confirmed 
by western blot using a mouse anti-FLAG 
monoclonal (1:2000 Sigma, St. Louis, MO) and 
rabbit anti-human CRF-BP antiserum (#5144; 
1:2000) (27). We initially constructed a series of 
truncated CRF-BP mutants to identify regions of 
CRF-BP involved in ligand binding, but none of 
these truncated CRF-BP mutants was detectable in 
the culture media following transient transfection 
(data not shown). All but eight of the CRF-BP 
alanine mutants were secreted following transient 
transfection in levels detectable by western blot 
(data not shown). While alanine mutations of 
aspartic acids at position 98 and 114 interfered 
with expression or secretion of CRF-BP 
(supplemental Table 1), CRF-BPD98N and CRF- 
BPD1 1 4 N were expressed and did not display gross 
abnormalities in the affinity for r/hCRF and rUcn 
1 (data not shown). CRF-BP was dialyzed 
overnight in 10 mM Hepes buffer pH 7.4 using 
dialysis tubes with 4 kDa MWCO (GBioscience, 
St. Louis, MO) and stored at -20°C. Controls 
transfected with vector DNA alone were included 
in all experiments and were consistently negative 
for the presence of FLAG-tagged protein or 
peptide binding activity.
CRF-BP LIRMA- CRF-BP mutants were 
quantified by ligand immuno-radiometric assay 
(LIRMA) as previously described (24). Briefly, 
serial dilutions of each mutant were incubated 
overnight at 4°C in 50 mM sodium phosphate 
buffer pH 7.5 containing 100 mM sodium 
chloride, 25 mM EDTA, 0.1% sodium azide, 0.1% 
crystalline BSA (MP Biomedicals ImmunO Grade, 
Irvine, CA) and 0.01% Triton-X 100 (EMD 
Biosciences, La Jolla, CA)) with 50,000 cpm
radiolabeled tracer in the presence of rabbit anti­
human CRF-BP antiserum (#5144; 1:1000) (27). 
For all experiments 125I-[D-Tyr0r/hCRF] was used 
as tracer, except for CRF-BP with mutations at 
positions 56 or 62 that interfere with r/hCRF 
binding, where 125I-[D-Tyr0rUcn 1] was used 
instead. We verified that the choice of tracer, 125I- 
[D-Tyr0r/hCRF] vs. 125I-[D-Tyr0rUcn 1], has no 
significant effect on Ki values (data not shown). 
Also, r/hCRF was capable of completely 
displacing 125I-[D-Tyr0rUcn 1] and rUcn1 
completely displaced 125I-[D-Tyr0r/hCRF] (data 
not shown). Iodination was carried out as 
previously described (28). Total counts bound 
were measured by precipitation for 2 h with sheep 
anti-rabbit y-globulin (1:20), normal rabbit serum 
(1:100) and 4% polyethylene glycol (PEG, 
average MW 8,000; Sigma, St. Louis, MO). For 
every mutant an appropriate working dilution was 
determined in the linear range of the assay, where 
an increase in CRF-BP was accompanied by linear 
increase in tracer binding. At that dilution, the 
affinities of CRF-BP mutants for CRF and Ucn 1 
were determined by competition with increasing 
amounts of unlabelled peptide. Binding curves and 
IC5 0  values including 95% confidence intervals 
were obtained using Prism 4.0c for Macintosh 
(Graphpad Software Inc., San Diego, CA, USA; 
www.graphpad.com). Curves were fitted by non­
linear regression assuming one site binding. All 
peptides were synthesized in-house using a tert- 
butyl-oxy-carbonyl strategy on an automated 
peptide sequencer (CS536 peptide synthesizer; C S 
Bio Co., San Carlos, CA) and purified by reverse 
phase HPLC and characterized by mass 
spectrometry.
In vitro reporter assay- HEK293T cells were 
seeded in a 10 cm dish at 1.5 x 106 cells per dish 
the day prior to transfection. The following day, 
cells were transiently transfected with 600 ng 
human CRFR1 in pcDNA3.1, 5 ^g pXP2 reporter 
construct (luciferase driven by a cAMP responsive 
element) and 1 ^g P-galactosidase driven by a 
CMV promoter (29). DNA was precipitated for 10 
min by incubation with 9.9 ^g PEI and added to 
the cells under serum-free conditions. The 
following day, cells were trypsinized and seeded
3
in poly-L-lysine coated wells of a 48 well plate at 
100,000 cells/well in media containing 10% fetal 
bovine serum. After an overnight rest, cells were 
stimulated for 3 h followed by a single wash with 
ice-cold Hepes dissociation buffer, HDB (28). 
Cells were lysed in 100 ^l luciferase buffer (10 
mM MgSO4, 25 mM glycylclycine, 4 mM EGTA) 
supplemented with 1% Triton X-100 (EMD 
Biosciences, La Jolla, CA) and 1 mM 
dithiothreitol (DTT). Luciferase activity was 
determined in 50 ^l cell lysate using a Lumimark 
plus microplate reader (Biorad, Hercules, CA) 
following addition of 100 ^l luciferin substrate 
buffer (luciferase buffer supplemented with 0.3 
mM luciferin, 1 mM ATP, 1mM DTT). Luciferase 
activity was normalized for the P-galactosidase 
activity measured in 20 ^l cell lysate by addition 
of 100 ^l p-galactosidase substrate buffer (60 mM 
Na2 HPO4 , 40 mM NaH2 PO4 , 10 mM KCl, 1 mM 
MgCl2, 50 mM P-mercapthoethanol, 1.5 mg/ml 
ortho-nitrophenyl-b-D-galactopyranoside; Sigma, 
St. Louis, MO).
Rat anterior pituitary assay- Purified CRF-BP 
mutants were tested on cultured primary rat 
anterior pituitary cells isolated from male Sprague 
Dawley rats and dispersed into single cells with 
collagenase as previously described (28). Cells 
were cultured at 6.2 x 104 cells per well in poly-L- 
lysine coated 96-well tissue culture plates (Costar, 
Cambridge, MA). Cultures were maintained in 0.1 
ml/well P-PJ (28) media containing 2% fetal 
bovine serum (FBS). On day 4 in culture, cells 
were washed three times with p-PJ media 
containing 0.1% BSA and incubated for 1 h at 
37°C. The media was replaced by treatment 
compounds diluted in P-PJ media containing 0.1% 
BSA. Media was harvested after 3 h and stored at - 
20°C until analysis for ACTH content. The 
procedure for ACTH radioimmunoassay was 
similar to that previously described for melanin- 
concentrating hormone (30), except that all buffers 
contained 0.05% Triton X-100. Rabbit anti-rat 
ACTH serum (Peninsula Laboratories, San Carlos, 
CA; T-4002) was used at 1:30,000 final dilution. 
(3-[125I]iodotyrosyl2) ACTH(1-39), purchased 
from Amersham Biosciences (Piscataway, NJ;
IM216) was used as tracer with ca. 20,000 cpm 
added per tube. Rat ACTH(1-39), synthesized in 
our laboratory, was used as standard at doses 
ranging from 2 - 1000 pg/tube. The EC50 for rat 
ACTH(1-39) was 65 - 70 pg/tube; the assay 
displays minimal cross-reactivity with aMSH and 
ACTH(1-24).
RESULTS
An alanine scan identifies residues that 
selectively affect binding o f  CRF or Ucn 1. We 
specifically disrupted the disulfide bridges of 
CRF-BP by mutating both cysteines of each pair to 
alanine. Only the CRF-BP mutants lacking the 
fourth or fifth disulfide bridge were expressed in 
detectable quantities, and their affinities for 
r/hCRF and rUcn 1 were unaffected (suppl. Fig.
1). This suggests that the key determinants for 
ligand binding are located towards the N-terminal 
part of CRF-BP. Based on this observation we 
initiated a comprehensive alanine scan of the N- 
terminal domain of hCRF-BP (31). In keeping 
with the argument that evolutionarily conserved 
residues are more likely to be involved in protein 
function, we targeted a panel of 76 residues that 
are conserved or conservatively substituted in 
CRF-BP of early vertebrate and insect species 
(suppl. Fig. 2). We determined the ability of all 
mutants to bind 125I-labeled r/hCRF and 125I- 
labeled rUcn 1 and compared each mutant to the 
binding capacity of wildtype (WT) CRF-BP (Fig.
1A). Mutation of several amino acids, notably 
W116 and Y211, completely abolished the ability 
of CRF-BP to bind CRF and Ucn 1, although 
mutant proteins were readily detectable by western 
immunoblotting (suppl. Fig. 3). As alanine 
substitutions of W116 and Y211 interfered with 
bioactivity in general, rather than specifically 
affecting affinity for r/hCRF or rUcn 1, it is 
possible that these mutations cause CRF-BP to 
misfold, resulting in loss of function. Similarly, 
mutants such as e.g. L61A, E121A, F123A and 
Q188A that have lost partial affinity for both 
r/hCRF and rUcn 1 may have done so because 
these mutations result in partial misfolding rather 
than specifically affecting the binding surface for 
the peptide ligands.
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We subsequently determined the relative 
potency of all CRF-BP mutants for binding to 
r/hCRF and rUcn 1 using competitive binding 
assays. For r/hCRF and rUcn 1 we identified 13 
and 14 alanine mutants, respectively, that had 
reduced affinity for the ligand by 2-fold or more 
(Fig. 1B; supplemental Table 1). Interestingly, we 
identified several amino acids that, when mutated, 
selectively affected the Ki for r/hCRF, but not 
rUcn 1, and vice versa. Residues that selectively 
affected the Ki for r/hCRF when substituted by 
alanine include R56 and D62 and, to a lesser 
extent, Y54, L58, L64 and F70. Residues that 
selectively or more potently interfered with high 
affinity binding to rUcn 1 when mutated include 
L61, M63, F84, E88, E91, Q188 and T189 (Fig.
1B). Generally, mutants that selectively altered 
r/hCRF affinity were concentrated towards the N- 
terminus, whereas mutations that 
disproportionately affected the binding of rUcn 1 
were distributed more evenly throughout the linear 
sequence of the N-terminal domain of CRF-BP.
CRF-BP does not require R46 and R59 to 
bind CRF or Ucn 1. Based on photo-crosslinking 
experiments, a pair of N-terminal arginines of 
CRF-BP, R46 and R59, were suggested to contact 
r/hCRF (26). As the involvement of R46 and R59 
in ligand binding had not been experimentally 
confirmed, we verified their contribution to the 
affinity for r/hCRF and rUcn 1. As shown in figure
2, WT recombinant C-terminally FLAG-tagged 
CRF-BP bound CRF and Ucn 1 with high affinity 
(Ki‘s for CRF and Ucn 1 are 217 and 77.2 pM, 
respectively), consistent with previously published 
values for non-tagged recombinant human CRF- 
BP (2,16,24). However, substitution of R46 with 
alanine did not affect Ki values for r/hCRF or rUcn 
1 whereas CRF-BPR59A displayed a modestly (<2­
fold) reduced Ki value for r/hCRF (Fig. 2). 
Simultaneous alanine substitution of R46 and R59 
resulted in a CRF-BP protein that was 
indistinguishable from hCRF-BP in its Ki for CRF 
and had slightly increased affinity for rUcn 1 (Fig.
2). Collectively, these data indicate that neither 
R46 nor R59 are key for binding to r/hCRF or to 
rUcn 1.
N-linked glycosylation at position 204 is 
not required for ligand binding. Alanine 
replacement of the asparagine comprising the 
single N-linked glycosylation site of CRF-BP 
(N204A) results in a reduction in molecular 
weight compared to WT CRF-BP, demonstrating 
that the N-linked glycosylation in transfected 
HEK293T cells is abrogated by the N204A 
mutation (Fig. 2E). In contradiction to an early 
report that N-linked glycosylation is required for 
CRF binding (23), the affinities of the N204A 
mutant for r/hCRF and rUcn 1 were 
indistinguishable from those of WT CRF-BP (Fig. 
2C,D).
Alanine substitution o f  R56 and D62 
selectively abrogates CRF binding. We focused in 
more detail on the profound and specific loss in 
affinity for CRF, but not Ucn 1, observed for 
CRF-BPR56A and CRF-BPD62A. Replacing either 
R56 or D62 with alanine reduced the affinity for 
r/hCRF by more than two orders of magnitude 
(Fig. 3A). Both mutations significantly affected 
CRF binding while affinity for rUcn 1 was only 
two-fold reduced (Fig. 3B). The selectivity of the 
R56A mutation was further illustrated by 
substituting the adjacent arginine at position 55 
(R55) with alanine, which had no effect on CRF 
binding (Fig. 3A). Substitution of R56 for a K 
only minimally improved the affinity for r/hCRF 
compared to CRF-BPR56A, while the introduction 
of an acidic amino acid side chain at this position 
failed to substantially alter the affinity for r/hCRF 
further compared to CRF-BPR56A (Fig. 3C). 
Substitution of D62 for an E resulted in a 10-fold 
loss of the affinity for r/hCRF, compared to the 
100-fold loss in affinity for CRF-BPR56A (Fig. 3D). 
CRF-BP mutants with a basic amino acid side 
chain in place of D62 did not express in detectable 
levels (data not shown).
As alanine substitutions of R56 and D62 
resulted in remarkably similar and approximately 
100-fold reductions in the affinity for r/hCRF 
while only marginally affecting the affinity for 
rUcn 1, we expressed CRF-BP with an 
R56A/D62A double mutation to test if the effects 
of the single mutations were additive. CRF- 
BPR56A/D62A bound r/hCRF with an affinity that was
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indistinguishable from that of either single mutant 
(Fig. 3A), demonstrating that the effects of the 
R56A and D62A mutations on r/hCRF binding 
were not cumulative. The affinity of R56A/D62A 
for rUcn 1 was unaffected (Fig. 3B). If R56 and 
D62 together form an intramolecular salt bridge, 
one would anticipate that switching both amino 
acids could restore the loss in affinity for r/hCRF 
caused by the removal of either amino acid. 
However, switching the amino acid residues at 
positions 56 and 62 (CRF-BPR56D/D62R) restores the 
affinity for r/hCRF merely four-fold compared to 
CRF-BPR5 6 A/D6 2 A, suggesting that the relationship 
between both amino acids may be more complex 
than a straightforward ionic interaction (Fig. 3D).
The side chain charge at ligand position 
25 determines the direction o f  the shift in affinity 
fo r  R56A and D62A. To identify candidate peptide 
residues or regions that could potentially act 
through R56 and D62 of CRF-BP, we compared 
the affinity of additional members of the CRF 
peptide family and investigated if these affinities 
are affected by the R56A or D62A mutations. As 
demonstrated earlier, CRF-BPR5 6 A and CRF- 
BPD62A displayed 100-fold reduced affinity for 
r/hCRF while leaving the affinity for rUcn 1 
largely intact (Fig. 4A,B). CRF-BP has high 
affinity (Ki of 163 pM) for carp urotensin-I (cUI), 
the bony fish ortholog of mammalian Ucn 1. This 
affinity was reduced by approximately 10-fold in 
both CRF-BPR5 6 A and CRF-BPD6 2 A (Fig. 4C). 
Affinity for mUcn 2, in contrast, was increased 
from 10.7 nM to 2.19 nM for CRF-BPR56A, while 
affinity of CRF-BPD6 2 A for mUcn 2 was unaffected 
(Fig. 4D). We inspected an amino acid sequence 
alignment of CRF family peptides (Fig. 4E) to 
identify differences between members that might 
explain the observed ligand-selective changes in 
affinity for CRF-BPR5 6 A and CRF-BPD6 2 A. The 
charge of the amino acid side chain at ligand 
position 25 correlated well with the direction and 
magnitude of the observed changes in affinity of 
CRF-BP for the different CRF-related ligands. 
Both r/hCRF and cUI have an acidic residue (E) at 
position 25 and bind with lower affinity upon 
removal of either R56 or D62 in CRF-BP, while 
the affinity for rUcn 1, which has a neutral
glutamine (Q) at position 25, is minimally affected 
by the R56A and D62A mutations. Conversely, 
mUcn 2 has a basic (K) residue at the equivalent 
amino acid position and responds to alanine 
substitution of R56 in CRF-BP with an increase in 
affinity.
To validate the involvement of E25 in 
r/hCRF in high affinity binding to CRF-BP, we 
replaced E25 with alanine in r/hCRF (r/hCRFE25A). 
We compared the effects of this mutation to 
alanine substitution of E2G (r/hCRFE2 GA), which is 
conserved in CRF, Ucn 1 and Ucn 2, as well as 
R23 (r/hCRFR2 3 A). The amino acids at positions 25 
and 23 in CRF have previously been shown to 
affect affinity for CRF-BP based on experiments 
with oCRF (24). The affinity of r/hCRFE2 5 A for 
CRF-BP was reduced by approximately two orders 
of magnitude, while the Ki of r/hCRFE2GA was only 
marginally (less than 2-fold) reduced compared to 
r/hCRF (Fig. 5A). Alanine substitution of R23 in 
CRF reduced the affinity of r/hCRF for CRF-BP 
by approximately seven-fold. When we 
determined the affinity of these r/hCRF analogs 
for R56A and D62A mutants of CRF-BP, we 
found that r/hCRFE25A no longer differed from 
r/hCRF in its affinity for CRF-BPR56A (Fig. 5B) 
and had only two-fold reduced affinity for CRF- 
BPD62A compared to r/hCRF (Fig. 5C). These 
results indicate that alanine replacement of E25 in 
r/hCRF had no further effect on the approximately 
lGG-fold reduction in affinity for CRF that results 
from the R56A or D62A mutations. In contrast, 
r/hCRFR23A did display a further reduction 
compared to r/hCRF in affinity for CRF-BP, in 
addition to the lGG-fold reduced affinity for CRF- 
BPR5 6 A and CRF-BPD6 2 A (Fig. 5). This 
demonstrates that the contribution of E25 in 
r/hCRF to the interaction with CRF-BP depends 
on the presence of both R56 and D62, while R23 
of r/hCRF affects affinity independently of these 
CRF-BP residues.
CRF-BPR56A and CRF-BPD62A inhibit Ucn 
1-induced activation o f  CRFR1 but have 
selectively lost the ability to inhibit CRF. We 
compared the ability of CRF-BPR56A and CRF- 
BPD62A to inhibit r/hCRF and rUcn 1-induced 
activation of CRFR1. Wildtype CRF-BP inhibited
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the activation of CRFR1 induced by 50 pM of 
r/hCRF or rUcn 1 with an IC50 of 2.65 and 8.01 
nM, respectively, as measured in a cAMP- 
luciferase reporter assay (Fig. 6A,B). In agreement 
with the profound and selective loss of binding 
affinity for r/hCRF, the CRF-BPR56A and CRF- 
BPD62A mutants displayed a severely and 
selectively reduced potency to inhibit the r/hCRF- 
induced activation of CRFR1 (Fig. 6A). In 
contrast, inhibition of rUcn 1-induced CRFR1 
activation was unaffected by R56A or D62A 
mutations (Fig. 6B). We then tested the ability of 
CRF-BP to inhibit the release of ACTH from 
primary rat anterior pituitary cultures induced by 
CRF or Ucn 1 via endogenous CRFR1. Wildtype 
CRF-BP at a concentration of 100 nM 
significantly inhibited the release of ACTH 
induced by increasing doses of CRF and Ucn 1. 
However, CRF-BPR5 6 A and CRF-BPD6 2 A do not 
inhibit r/hCRF-induced ACTH release (Fig. 6C), 
while maintaining a potency similar to WT CRF- 
BP in inhibiting the ACTH release induced by 
rUcn 1 (Fig. 6D).
In a reverse approach, we tested the ability 
of WT CRF-BP to block the activation of CRFR1 
by r/hCRF and r/hCRFE25A. Wildtype CRF-BP 
robustly inhibited r/hCRF, as the EC50 for r/hCRF 
was shifted by approximately 30-fold in the 
presence of CRF-BP (Fig. 7A). In contrast, CRF- 
BP was incapable of inhibiting the activation of 
CRFR1 by r/hCRFE25A in line with the profoundly 
reduced affinity of r/hCRFE25A for CRF-BP. The 
potency of r/hCRFE25A to activate CRFR1 was 
equal to that of r/hCRF. When we compared the 
induction of ACTH release from rat primary 
anterior pituitary cells by r/hCRF and r/hCRFE25A, 
we found that r/hCRFE2 5 A was slightly more potent 
in inducing ACTH release compared to r/hCRF, 
but that this induction was no longer antagonized 
by CRF-BP (Fig. 7B).
DISCUSSION
Considerable progress has been made in 
recent years to identify the molecular determinants 
that direct the interaction of CRF family ligands 
with their cognate receptors (9-12). Yet, little 
attention has been paid to the binding surface on
CRF-BP responsible for the high affinity 
interactions between CRF-BP and its endogenous 
ligands CRF and Ucn 1. To address this hiatus, we 
initiated a mutagenesis approach that involved a 
comprehensive alanine scan of CRF-BP. We 
focused on the N-terminal 27 kDa domain of CRF- 
BP, as disruption of either of the two C-terminal 
disulfide bridges had no effect on the affinity for 
r/hCRF and rUcn 1. This is in agreement with 
earlier observations that CRF-BP undergoes 
spontaneous cleavage after serine 234, resulting in 
an inactive lG kDa C-terminal fragment and a 27 
kDa N-terminal fragment that retains the ability to 
bind CRF (31). Our approach revealed multiple 
amino acids in CRF-BP that differentially or 
selectively affect the binding of r/hCRF or rUcn 1 
when replaced by alanine. As r/hCRF and rUcn 1 
compete for binding to CRF-BP it is probable that 
both peptides occupy partially overlapping areas 
on the surface of CRF-BP. From the differences in 
amino acid positions of CRF-BP that affect the 
affinity of r/hCRF and rUcn 1, and the discovery 
that many of these residues differentially affect the 
affinity for either peptide, it follows that r/hCRF 
and rUcn l depend in part on distinct molecular 
interactions to bind to CRF-BP with similarly high 
affinity.
Two N-terminal arginine residues, R46 
and R59, were previously suggested to be part of 
the binding site on CRF-BP for CRF based on 
photocrosslinking studies (26). The coincidental 
similarities of the distances between the N- and C- 
terminus of a-helical CRF(6-33) and the side chains 
of R46 and R59 of CRF-BP in a linear 
arrangement led to the postulation that the 
interface between CRF and CRF-BP consists of 
two antiparallel polypeptides (26). However, no 
mutagenesis experiments were conducted to test 
the validity of this model. We have now replaced 
R46 and R59 with alanine, both individually and 
in combination, and found that mutation of these 
residues only minimally affects the affinity of 
CRF-BP for r/hCRF or rUcn 1. Although this does 
not rule out the possibility that R46 and/or R59 are 
situated in proximity to the actual binding surface 
for CRF in CRF-BP, it demonstrates that neither 
residue contributes substantially to peptide 
binding.
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A dramatic example of the ligand-specific 
events involved in binding CRF, but not Ucn 1, is 
provided by CRF-BPR56A and CRF-BPD62A. These 
CRF-BP mutants each display a selectively 
reduced affinity for r/hCRF of approximately two 
orders of magnitude, coupled with only marginally 
reduced affinity for rUcn 1. Furthermore, the 
remarkably similar effects of both mutations are 
not cumulative, prompting the possibility of a 
direct ionic interaction. However, switching of the 
amino acids at positions 56 and 62 fails to restore 
the affinity for r/hCRF, suggesting that these 
residues may interact in a more complex fashion. 
Alanine substitution of E25 in CRF results in a 
comparable decrease in affinity that requires the 
presence of both R56 and D62 in CRF-BP, as the 
alanine replacement of either CRF-BP residue 
abrogates the large difference in affinity between 
r/hCRF and r/hCRFE25A. Collectively, this suggests 
that R56 and D62 in CRF-BP and E25 in r/hCRF 
participate in the same molecular interaction. It is 
possible that these amino acids engage in a 
composite interaction that requires all three 
residues, as removal of any one of them is 
sufficient for the full shift in affinity of two orders 
of magnitude. One possible explanation is the 
formation of a salt bridge triad that has been 
observed in a number of proteins (32-35). In these 
proteins, two residues with organic acid side 
chains and one with a basic side chain (or vice 
versa) interlock in a small network of salt bridges 
and hydrogen bonds that greatly stabilize protein 
structure. Alternatively, it is possible that 
substitution of R56 and D62 by alanine confers a 
structural change in CRF-BP that indirectly 
interferes with high affinity binding to r/hCRF.
Previous experiments with modified oCRF 
peptides demonstrated a key role for the four- 
amino acid ARAE motif at positions 22-25 of the 
ligand (24,36). Here we confirm the role of R23 
and E25 in the interaction between r/hCRF and 
CRF-BP, as alanine substitution of these peptide 
residues results in a loss of affinity of 7- and 80­
fold, respectively. A closer inspection of the core 
residues of CRF in their a-helical conformation 
reveals that E25 and R23 are the only polar 
residues amidst an otherwise hydrophobic face of 
the a-helical CRF peptide (37,38). The amino acid
side chains of R23 and E25 occupy the same face 
of the CRF peptide but point in opposite directions 
(Fig. 8). Of note, the substitution of A22 in 
r/hCRF with glutamic acid reduces the affinity for 
CRF-BP by approximately 100-fold (25). Perhaps 
replacing the small side chain of an alanine that 
has high a-helical propensity with the larger and 
acidic side chain of glutamic acid interferes with 
the same intra- and inter-molecular interactions 
that require the presence of R56 and D62 in CRF- 
BP and E25 in r/hCRF. It is conceivable that 
within the ARAE motif of r/hCRF, R23 and E25 
directly interact with the binding surface of CRF- 
BP, whereas the role of the alanines at positions 22 
and 24 may be to prevent steric hindrance, 
promote peptide a-helicity, or both.
Early studies comparing the duration of 
oCRF and r/hCRF action following bolus injection 
in the human circulation found that oCRF was 
consistently longer acting and was cleared at an 
approximately three-fold lower rate compared to 
r/hCRF (39). CRF-BP is suspected of actively 
clearing r/hCRF, but not oCRF for which it has 
only low affinity, from the circulation (40,41). By 
introducing a single E25A amino acid substitution 
in r/hCRF, we generated a peptide that is 
equipotent to endogenous r/hCRF in its activation 
of CRFR1 but that may no longer be actively 
cleared from the circulation or inhibited from 
receptor activation by CRF-BP.
Our discovery that different regions of 
CRF-BP contribute to the binding of CRF and Ucn 
1 opens new avenues for the specific abrogation of 
selected CRF family members. Traditionally, 
intervention of pathologies associated with 
dysregulated signaling by CRF family peptides has 
aimed at the selective activation or antagonism of 
CRFRs. Selective receptor antagonists are 
available for CRFR1 (e.g. antalarmin) and CRFR2 
(antisauvagine-30, Astressin2-B) (7,42-44). The 
identification of residues that selectively affect the 
affinity of CRF-BP for CRF family peptides 
facilitates the design of ligand-specific antagonists 
that could be used as alternatives for, or 
complimentary to, selective receptor antagonists.
With the introduction of a single alanine 
mutation (R56A) in CRF-BP we effectively 
created a Ucn 1-specific antagonist. Although the
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generally beneficial effects of Ucn 1 on 
cardiovascular performance (2,8,45,46) may limit 
the clinical potential of a CRF-BP based Ucn 1- 
specific antagonist, this antagonist could be a 
valuable tool to discriminate between the effects 
of Ucnl and CRF on CRF receptors. In light of the 
recent observation that Ucn 2 reduces peripheral 
insulin sensitivity (47), the design of a Ucn 2- 
selective antagonist based on CRF-BP holds 
promise to protect from or alleviate metabolic 
insults that lead to obesity and type-II diabetes.
CRF is implicated in the etiology of 
Alzheimer’s disease (AD). It is expressed in brain 
regions that are prone to degeneration in AD and 
lower CRF levels in the CSF of patients correlate 
with greater cognitive impairment (48-51). As 
CRF-BP is highly expressed in areas affected by 
AD, but is sparse at sites where liberation of 
endogenous CRF would result in unfavorable
stress and anxiety-like side effects, the 
administration of ligands that are incapable of 
receptor activation but can dissociate endogenous 
CRF from CRF-BP has been proposed for the 
treatment of AD (52). We anticipate that intimate 
knowledge of the mechanisms by which CRF and 
CRF-BP interact provides impetus for the 
development of CRF-BP antagonists that may 
locally compete with endogenous CRF for CRF- 
BP. The identification of R56 and D62 as amino 
acids key for binding CRF, but not Ucn 1, may 
further the design of antagonists that selectively 
prevent the interaction between CRF and CRF-BP. 
A complete understanding of the interactions 
between CRF-BP and its endogenous ligands, 
including those residues responsible for ligand 
selectivity, awaits the resolution of the three­
dimensional structure of CRF-BP.
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FIGURE LEGENDS
Fig. 1. Summary of the effect of alanine substitution of selected residues of human CRF-BP on 
maximum r/hCRF or rUcn 1 binding (A). Serial dilutions of each mutant were incubated with a fixed 
amount of 125I-[D-Tyr0r/hCRF] or 125I-[D-Tyr0rUcn 1]. The amount of bound radioligand increases with 
increasing concentrations of CRF-BP, until it reaches a maximum and starts to decrease with increasing 
CRF-BP concentration, when the capacity of the CRF-BP antiserum is no longer sufficient to capture all 
CRF-BP (inset). The maximum tracer binding capacity is an approximate indicator of affinity. For 
example (inset), CRF-BPY54A binds approximately 25% of the tracer that is bound by WT CRF-BP, 
indicative of reduced affinity for r/hCRF. Using this method we determined the maximum tracer binding 
capacity for each alanine mutant in duplicate for independently expressed and purified CRF-BP 
preparations using r/hCRF and rUcn 1 tracer. We expressed these maxima relative to the maximal 125I-[D- 
Tyr0r/hCRF] (circles, solid line) and 125I-[D-Tyr0rUcn 1] (boxes, dashed line) binding capacity of WT 
CRF-BP, which was defined as 100%. Alanine substitutions that affect the affinity for r/hCRF and/or
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rücn 1 are characterized by a decrease in their percent of maximal binding. Changes in relative potency 
were determined separately by competitive binding assays (B). Only mutants that affect affinity for either 
peptide by two-fold or more are shown. Note that CRF-BPw116a and CRF-BPY2nA could not be 
determined as they do not bind detectable amounts of r/hCRF or rücn 1 tracer. See supplemental table 1 
for a comprehensive list of the relative potency for all mutants.
Fig. 2. R46, R59 and N204 in CRF-BP are dispensable for high affinity binding to r/hCRF or 
rücn 1. Percent displacement (% B/B0) of 125I-[D-Tyr0r/hCRF] by r/hCRF or rücn 1, comparing wildtype 
(WT) CRF-BP with CRF-BPR46A, CRF-BPR59A and CRF-BPR46A/R59A. WT CRF-BP (open symbols, dashed 
lines) binds rücn 1 with slightly higher affinity than r/hCRF. Alanine substitution of R46 does not affect 
affinity for either peptide, while the affinity for r/hCRF is less than two-fold reduced in CRF-BPR59A 
(A,B). Simultaneous mutation of R46 and R59 has no effect on the affinity for r/hCRF and slightly 
improves binding to rücn 1 (B). Note that R46 and R59 are referred to as R23 and R36 in (26). The 
affinity of CRF- BPN204A (closed symbols, solid line) for r/hCRF (C) or rücn 1 (D) is not different from 
that of WT CRF-BP (open symbols, dashed line). CRF-BPN204A has a lower apparent molecular weight 
than WT CRF-BP as determined by SDS-page and detected by western immunoblot (E), confirming that 
N-linked glycosylation in HEK293T cells is prevented by the N204A mutation. Ki values and 95% 
confidence intervals are derived from two or more separate experiments.
Fig. 3. Amino acid substitutions at CRF-BP position 56 and 62 differentially affect affinities for 
r/hCRF and rücn 1. Alanine substitution of R56 or D62 results in profound and similar reductions in the 
affinity for r/hCRF (A). Simultaneous substitutions of R56 and D62 does not further reduce the affinity 
for r/hCRF. The affinity for r/hCRF is unaffected by alanine substitution of R55. In contrast to the 
profound changes in affinity for r/hCRF, CRF-BPR56A and CRF-BPD62A have only two-fold reduced 
affinity for rücn 1 (B). Simultaneous substitution of R56 and D62 for alanines does not affect rücn 1 
affinity. Substitution of R56 for a K only minimally restores affinity for r/hCRF, while the introduction of 
acidic amino acids at this position did not further reduce the affinity for r/hCRF compared to CRF-BPR56A 
(C). Substitution of D62 for an E restores the affinity for r/hCRF by approximately 10-fold when 
compared to CRF-BPD62A (D). Switching the residues at positions 56 and 62 (CRF-BPR56D/D62R) fails to 
restore the affinity for r/hCRF to levels comparable to the affinity of WT CRF-BP. In all experiments 125I- 
[D-Tyr0rücn 1] was used as tracer with the exception of the competitive binding assays with CRF-BPR55A, 
where 125I-[D-Tyr0r/hCRF] was used. Ki values and 95% confidence intervals are derived from two or 
more separate experiments.
Fig. 4. The direction and severity of the change in affinity for CRF family peptides correlates 
with the charge of the amino acid side chain at position 25 of the ligand. CRF-BPR56A and CRF-BPD62A 
have 100-fold and 10-fold reductions in affinity for r/hCRF (A) and carp urotensin I (C), respectively. 
Affinity for rücn 1 is reduced by less than two-fold (B). In contrast, CRF-BPR56A has increased affinity 
for m ücn 2, while alanine substitution of D62 has no effect on m ücn 2 affinity (D). Note that the reduced 
affinity of r/hCRF and cüI correlates with a glutamic acid at position 25, while m ücn 2 has a basic lysine 
at the equivalent position and displays increased affinity for CRF-BPR56A. The minor effects of either 
CRF-BP mutant on rücn 1 affinity correspond with the absence of an organic base or acid in the side 
chain of amino acid position 25 (E). In all experiments 125I-[D-Tyr0rücn 1] was used as tracer. Ki values 
and 95% confidence intervals are derived from two or more separate experiments.
Fig. 5. Substitution of E25 in r/hCRF affects its affinity for CRF-BP only in the presence of both 
R56 and D62 in CRF-BP. The affinity of r/hCRF is reduced by 80-fold following alanine substitution of 
E25, while alanine substitution of E20 has no effect on binding to CRF-BP (A). Alanine substitution of
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R23 reduces the affinity of r/hCRF by approximately one order of magnitude. The profound loss in 
affinity of r/hCRFE25A for CRF-BP is absent on the background of CRF-BPR56A (B) or CRF-BPD62A (C), 
suggesting that E25 in r/hCRF requires R56 and D62 to interact with CRF-BP. In contrast, replacing R23 
by alanine continues to reduce affinity of r/hCRF for CRF-BPR56A and CRF-BPD62A, demonstrating that 
R23 interacts with CRF-BP independently of R56 and D62 in the binding protein. The position of the 
alanine substitutions within r/hCRF is illustrated in panel D. In all experiments 125I-[D-Tyr°rUcn 1] was 
used as tracer. Ki values and 95% confidence intervals are derived from two or more separate 
experiments.
Fig. 6. CRF-BPR56A and CRF-BPD62A have selectively lost the ability to inhibit r/hCRF-induced 
activation of CRFR1. Wildtype CRF-BP dose-dependently inhibits r/hCRF-induced (50 pM) activation of 
CRFR1 as measured by cAMP-responsive element-driven luciferase activity (A). This dose-dependent 
inhibition is greatly impaired in CRF-BPR5 6 A and CRF-BPD6 2 A. In contrast, both CRF-BP mutants retain 
the ability to inhibit rUcn 1-induced (50 pM) activation of CRFR1 with similar potency to WT CRF-BP 
(B). Wildtype CRF-BP inhibits the r/hCRF-induced release of ACTH from primary rat anterior pituitary 
cultures, but both CRF-BPR5 6 A and CRF-BPD6 2 A have lost the ability to inhibit r/hCRF-induced ACTH 
release (C). In contrast, both CRF-BP mutants retain the ability to inhibit rUcn 1-induced release of 
ACTH with the same potency as WT CRF-BP (D).
Fig. 7. Alanine substitution of E25 in r/hCRF creates a ligand that activates CRFR1 with equal or 
greater potency than r/hCRF but is no longer inhibited by CRF-BP. CRFR1 is activated in a dose- 
dependent fashion and with equal potency by r/hCRF and r/hCRFE25A as measured by luciferase activity 
(A). However, addition of CRF-BP inhibits only the r/hCRF-induced CRFR1 activation. Similarly, 
r/hCRF and r/hCRFE25A both induce ACTH release from primary rat anterior pituitary cell cultures, but 
addition of CRF-BP no longer inhibits r/hCRFE2 5 A-induced ACTH release (B).
Fig. 8. Schematic representation of part of the N-terminus of human CRF-BP, highlighting the 
amino acid positions where alanine substitution affects the affinity for r/hCRF or rUcn 1. Positions where 
alanine substitution results in a reduction of the affinity for r/hCRF of two-fold or more are orange, R56 
and D62 are red. The residues that are indicated by a bold circle indicate positions where alanine 
substitution reduces rUcn 1 affinity by at least two-fold. The three-dimensional structure of the central 
part of CRF illustrates that the amino acid side chains of glutamine 25 and arginine 23 are situated on the 
same face of the ligand and point in opposite directions. The dashed lines connecting E25 of CRF with 
R56 and D62 of CRF-BP indicate that high affinity binding of r/hCRF by CRF-BP depends on 
interactions that directly or indirectly require all three residues. The three-dimensional structure is derived 
from the NMR structure of astressin (2RMI), which is identical to r/hCRF in the central region of the 
peptide that is depicted (E17 to Q29) with the exception of a methionine to norleucine subsitution at 
position 21.
Suppl. Fig. 1. Removal of the cysteines forming the fourth (C237/C264) or fifth (C277/C318) 
disulfide bridge of CRF-BP has no effect on the affinities for r/hCRF or rUcn 1. Percent displacement (% 
B/B0) of 125I-[D-Tyr0r/hCRF] by r/hCRF (A) or rUcn 1 (B) demonstrates that the affinity of CRF- 
BPC237A/C264A and CRF-BPC277A/C3i8A for r/hCRF or rUcn 1 is indistinguishable from that of WT CRF-BP 
(open symbols, dashed line). Ki values and 95% confidence intervals are derived from two or more 
separate experiments.
Suppl. Fig. 2. Multiple amino acid alignment of CRF-BP sequences from selected vertebrate and 
invertebrate species. Amino acids targeted as part of our alanine scan are shaded. Asterisks indicate
13
amino acid identity between all sequences in the alignment, while colons and dots indicate decreasing 
degrees of amino acid similarity. Accession numbers are as follows: human (Homo sapiens), P24387; 
mouse (Mus musculus), Q60571; chicken (Gallus gallus), XM_424801; Xenopus (Xenopus laevis), 
Q91653; carp (Cyprinus carpio), AJ490880; honey bee (Apis mellifera), AJ780964.
Suppl. Fig. 3. Western immunoblot of wild type (WT) CRF-BP and mutants that display partial 
(L61A, E121A, F123A, Q188A) or complete (W116A, Y211A) loss of affinity for both r/hCRF and rUcn 
1. All mutant proteins express in similar levels compared to WT CRF-BP and have indistinguishable 
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11 -10 -9 
log [Ucn 1]
K, (nM) 95% conf. interv. K, (nM) 95% conf. interv.
O WT 0.217 (0.196 to 0.240) O WT 0.0772 (0.0676 to 0.0880)
▲  R46A 0.228 (0.185 to 0.280) ▲  R46A 0.0846 (0.0718 to 0.0996)
▼  R59A 0.370 ( 0.304 to 0.451) T  R59A 0.0757 (0.0623 to 0.0920)
♦  R46A/R59A 0.217 (0.178 to 0.266) ♦  R46A/R59A 0.0470 (0.0394 to 0.0559)
r/hCRF D rilen 1 E <
oCM
-12 -11 -10 -9 
log [CRF]
K¡ (nM) 95% conf. interv.
■11 -10 -9 
log [Ucn 1]
K¡ (nM) 95% conf. interv.
O WT 0.116 (0.106 to 0.127) O WT 0.119 ( 0.111 to 0.128 )
▲  N204A 0.145 ( 0.125 to 0.180) A N204A 0.124 ( 0.112 to 0.137)
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▲ R56A 24.5 ( 20.9 to 28.7 ) ▼ D62A 20.5 ( 17.1 to 24.6
▼ R56K 10.4 ( 8.97 to 12.0 ) A D62E 1.80 ( 1.51 to2.15
■ R56E 37.4 ( 28.9 to 48.3 ) ♦ R56D/D62R 5.27 ( 3.96 to 7.03
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IC50 (nM) 95% conf. interv.
O WT 2.65 ( 2.00 to 3.52 )
▲  R56A 460 ( 307 to 689 )
▼  D62A >100 ( n.a. )
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log [CRF]
EC jo (nM) 95% conf. interv.
O CRF 0.624 ( 0.366 to 1.07 )
■ CRF + 100 nM WT 4.49 ( 2.68 to 7.51 ) 
A  CRF + 100 nM R56A 0.680 ( 0.428 to 1.08 )
▼  CRF + 100 nM D62A 0.129 (0.0663 to 0.250)
D  rUcn 1
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r/hCRF vs r/hCRF E25A
log [CRF]
EC50 (nM) 95% conf. interv.
0.182 ( 0.103 to 0.320 )
4.99 (  3.58 to 6.96 )
0.222 (  0.133 to 0.370 )
CRFE25A + 50 nM CRF-BP 0.190 (  0.119 to 0.305 )
O  CRF
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